Relief Therapeutics Holding AG (RLFTF)
USD 4.9
(0.0%)
USD 4.9
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -10.24 Million CHF | 36.65% |
| 2022 | -16.17 Million CHF | 61.26% |
| 2021 | -41.74 Million CHF | -12.31% |
| 2020 | -37.17 Million CHF | -4562.18% |
| 2019 | 833 Thousand CHF | -80.96% |
| 2018 | 4.37 Million CHF | 398.86% |
| 2017 | 877 Thousand CHF | 81.2% |
| 2016 | 484 Thousand CHF | -88.67% |
| 2015 | 4.27 Million CHF | 486.58% |
| 2014 | -1.1 Million CHF | -114.72% |
| 2013 | 7.5 Million CHF | 211.71% |
| 2012 | 2.4 Million CHF | 313.51% |
| 2011 | -1.12 Million CHF | 43.67% |
| 2010 | -2 Million CHF | 53.45% |
| 2009 | -4.3 Million CHF | 68.31% |
| 2008 | -13.56 Million CHF | -87.52% |
| 2007 | -7.23 Million CHF | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -10.71 Million CHF | -4.6% |
| 2024 Q2 | -10.71 Million CHF | 22.44% |
| 2023 Q2 | -9.55 Million CHF | -8.92% |
| 2023 FY | -10.24 Million CHF | 36.65% |
| 2023 Q4 | -10.24 Million CHF | 4.87% |
| 2023 Q3 | -10.76 Million CHF | -12.73% |
| 2023 Q1 | -8.77 Million CHF | 45.77% |
| 2022 Q4 | -16.17 Million CHF | -5.45% |
| 2022 Q1 | -26.15 Million CHF | 37.36% |
| 2022 Q3 | -15.33 Million CHF | 43.3% |
| 2022 FY | -16.17 Million CHF | 61.26% |
| 2022 Q2 | -27.04 Million CHF | -3.43% |
| 2021 Q4 | -41.74 Million CHF | -2.25% |
| 2021 FY | -41.74 Million CHF | -12.31% |
| 2021 Q1 | -9.05 Million CHF | 75.64% |
| 2021 Q2 | -9.91 Million CHF | -9.51% |
| 2021 Q3 | -40.82 Million CHF | -311.82% |
| 2020 Q4 | -37.17 Million CHF | 0.0% |
| 2020 Q2 | 77 Thousand CHF | -95.58% |
| 2020 Q1 | 1.74 Million CHF | 109.0% |
| 2020 FY | -37.17 Million CHF | -4562.18% |
| 2020 Q3 | -37.17 Million CHF | -48372.73% |
| 2019 FY | 833 Thousand CHF | -80.96% |
| 2019 Q4 | 833 Thousand CHF | -48.26% |
| 2019 Q1 | 1.27 Million CHF | -70.79% |
| 2019 Q2 | 642 Thousand CHF | -49.77% |
| 2019 Q3 | 1.61 Million CHF | 150.78% |
| 2018 Q2 | 5.25 Million CHF | 486.72% |
| 2018 Q4 | 4.37 Million CHF | 455.2% |
| 2018 FY | 4.37 Million CHF | 398.86% |
| 2018 Q3 | 788 Thousand CHF | -85.01% |
| 2018 Q1 | 896 Thousand CHF | 2.17% |
| 2017 FY | 877 Thousand CHF | 81.2% |
| 2017 Q4 | 877 Thousand CHF | 0.0% |
| 2017 Q3 | 877 Thousand CHF | 33.89% |
| 2017 Q2 | 655 Thousand CHF | 0.0% |
| 2017 Q1 | 655 Thousand CHF | 35.33% |
| 2016 FY | 484 Thousand CHF | -88.67% |
| 2016 Q4 | 484 Thousand CHF | 0.0% |
| 2016 Q3 | 484 Thousand CHF | -85.18% |
| 2016 Q2 | 3.26 Million CHF | 25023.08% |
| 2016 Q1 | 13 Thousand CHF | -99.7% |
| 2015 Q2 | 1.8 Million CHF | 0.0% |
| 2015 FY | 4.27 Million CHF | 486.58% |
| 2015 Q4 | 4.27 Million CHF | 0.0% |
| 2014 Q4 | -1.1 Million CHF | 0.0% |
| 2014 FY | -1.1 Million CHF | -114.72% |
| 2014 Q2 | 7.37 Million CHF | 0.0% |
| 2013 FY | 7.5 Million CHF | 211.71% |
| 2013 Q2 | 2.18 Million CHF | 0.0% |
| 2013 Q4 | 7.5 Million CHF | 0.0% |
| 2012 Q4 | 2.4 Million CHF | 0.0% |
| 2012 FY | 2.4 Million CHF | 313.51% |
| 2012 Q2 | 1.6 Million CHF | 0.0% |
| 2011 FY | -1.12 Million CHF | 43.67% |
| 2011 Q2 | -3.92 Million CHF | 0.0% |
| 2011 Q4 | -1.12 Million CHF | 0.0% |
| 2010 Q2 | -2.63 Million CHF | 0.0% |
| 2010 FY | -2 Million CHF | 53.45% |
| 2010 Q4 | -2 Million CHF | 0.0% |
| 2009 Q4 | -4.3 Million CHF | 0.0% |
| 2009 Q2 | -7.22 Million CHF | 0.0% |
| 2009 FY | -4.3 Million CHF | 68.31% |
| 2008 FY | -13.56 Million CHF | -87.52% |
| 2008 Q4 | -13.56 Million CHF | 0.0% |
| 2007 FY | -7.23 Million CHF | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 164.994% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 348.784% |
| SQZ Biotechnologies Company | -36.23 Million USD | 71.729% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 123.941% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -62.502% |
| Mesoblast Limited | 55.85 Million USD | 118.341% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 1204.956% |
| Genus plc | 190.6 Million USD | 105.375% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 558.219% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 943.982% |
| Marizyme, Inc. | 18.56 Million USD | 155.173% |
| ContraFect Corporation | -6.02 Million USD | -70.013% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 1606.618% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 7709.237% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 986.684% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 556.911% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 286.209% |
| MultiCell Technologies, Inc. | 90.04 USD | 11378376.322% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -1295.818% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 179.136% |
| EV Biologics, Inc. | 1.36 Million USD | 848.919% |
| Q BioMed Inc. | 4.06 Million USD | 352.339% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 133.531% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 1746.143% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 1116.655% |
| Biomind Labs Inc. | 711.4 Thousand USD | 1540.114% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 109.33% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 179.998% |
| Skye Bioscience, Inc. | -5.72 Million USD | -79.065% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 1290.945% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 7428.117% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 281.38% |
| IMV Inc. | 7.67 Million USD | 233.563% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 51667.927% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 565.263% |
| GB Sciences, Inc. | 1.74 Million USD | 686.328% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -5474.357% |
| HST Global, Inc. | 96.79 Thousand USD | 10684.443% |
| CSL Limited | 10.52 Billion USD | 100.097% |
| Halberd Corporation | 144.72 Thousand USD | 7179.138% |
| Enzolytics Inc. | 981.65 Thousand USD | 1143.645% |
| Resverlogix Corp. | 6.45 Million USD | 258.813% |
| Affymax, Inc. | -5.59 Million USD | -83.044% |
| SYBLEU INC | 473.71 Thousand USD | 2262.697% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -1422.087% |
| argenx SE | -2.02 Billion USD | 99.495% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 123.588% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 78.208% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 478.238% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -15.895% |
| AVAX Technologies, Inc. | -5.9 Million USD | -73.55% |
| Zenith Capital Corp. | 10.06 Thousand USD | 101898.49% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.035% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 5211.459% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 529.374% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 6327.623% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 116.921% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 612.406% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | -298.633% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 2948.128% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 150.528% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -55828.595% |
| BioStem Technologies, Inc. | 4.47 Million USD | 329.092% |
| ONE Bio Corp. | 9.04 Million USD | 213.329% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 5190.582% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -781961.069% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 5068.068% |
| Agentix Corp. | 37.63 Thousand USD | 27324.894% |
| LadRx Corporation | -2.03 Million USD | -403.077% |
| Cell Source, Inc. | 9.23 Million USD | 210.973% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -50100.902% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1712.962% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1712.962% |
| NovAccess Global Inc. | 2.17 Million USD | 570.285% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 244.888% |
| Itoco Inc. | 228.3 Thousand USD | 4587.418% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 7633.698% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 306.677% |
| Kadimastem Ltd | -253.1 Thousand USD | -3947.775% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 2649.465% |
| CytoDyn Inc. | 20.26 Million USD | 150.563% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -1583362.133% |
| Mobile Lads Corp. | 484.23 Thousand USD | 2215.721% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -110437.594% |
| Qrons Inc. | 351.42 Thousand USD | 3015.257% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 232.948% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -4004.238% |
| Rebus Holdings, Inc. | 305 Thousand USD | 3459.016% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 329.862% |
| International Stem Cell Corporation | 2.59 Million USD | 495.56% |
| Bioxytran, Inc. | 1.89 Million USD | 639.519% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 16514.849% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 569.76% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 398.34% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 219.783% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 1426.03% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -719.6% |
| Neutra Corp. | 52.18 Thousand USD | 19731.326% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -311.611% |
| PureTech Health plc | -167.19 Million USD | 93.872% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -4083.203% |
| IXICO plc | -4.44 Million USD | -130.505% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 177.502% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 118.678% |
| CSL Limited | 10.52 Billion USD | 100.097% |
| Cellectis S.A. | -43.81 Million USD | 76.62% |